Table 1

Summary of baseline biomarker-defined subgroup efficacy at 24 weeks in the ADACTA trial
Biomarker subset, number ADA ACR20 (%) ADA ACR50 (%) ADA ACR70 (%) ADA ∆DAS28-ESR (±SE) ACR50 odds ratio ADA versus TCZ (95% CI)
sICAM1high/CXCL13low (26) 73 42 23 -2.3 (±0.37) 2.93 (0.7-15.2)
sICAM1low/CXCL13high (15) 27 13 7 -1.1 (±0.33) 0.07 (0.009-0.3)
sICAM1high/CXCL13high (32) 50 28 19 -2.1 (±0.31) 0.53 (0.17-1.6)
sICAM1low/CXCL13low (33) 52 24 18 -2.1 (±0.32) 0.41 (0.13-1.2)
Biomarker subset, number TCZ ACR20 (%) TCZ ACR50 (%) TCZ ACR70 (%) TCZ ∆DAS28-ESR (±SE) ACR50 odds ratio TCZ vs. ADA (95% CI)
sICAM1high/CXCL13low (15) 60 20 7 -3.2 (±0.37) 0.34 (0.07-1.4)
sICAM1low/CXCL13high (26) 81 69 50 -3.6 (±0.32) 14.6 (3.1-108.9)
sICAM1high/CXCL13high (26) 58 42 31 -3.2 (±0.37) 1.9 (0.63-5.73)
sICAM1low/CXCL13low (25) 60 44 24 -2.9 (±0.36) 2.5 (0.8-7.8)

Data are shown for American College of Rheumatology (ACR) 20, 50 and 70 response rates, change in disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) (± standard error, SE), and odds ratio with 95% CI for ACR50 response. ADA, adalimumab (anti-TNFα); TCZ, tocilizumab (anti-IL-6R).

Dennis et al.

Dennis et al. Arthritis Research & Therapy 2014 16:R90   doi:10.1186/ar4555

Open Data